Purpose
The BPC-157 + TB-500 combination is the most-discussed stack in the peptide-recovery research literature. The rationale in preclinical writeups is that the two peptides act on distinct axes of the tissue-repair response:
- BPC-157 — short half-life, local angiogenic and cytoprotective effects; typically administered near the injury site in animal studies.
- TB-500 — longer-acting systemic peptide with actin-sequestering activity that supports cell migration and angiogenesis during the repair phase.
Component peptides
- BPC-157 — reported dose range 200–500 mcg, once or twice daily, subcutaneous.
- TB-500 — reported dose range 2,000–5,000 mcg, two or three times per week, subcutaneous.
Timing & rotation
Research writeups typically describe a 4-week concurrent administration period, followed by a 4-week washout during which the tissue is allowed to complete remodelling without ongoing intervention. Some protocols continue BPC-157 through the washout at a reduced frequency for symptomatic tissue while stopping TB-500.
The cycling rationale in the literature is twofold: to allow assessment of whether tissue-repair effects persist beyond the administration window, and — for TB-500 in particular — to keep total systemic exposure bounded.
Reconstitution & math
Both peptides are typically supplied as 5 mg lyophilised vials and reconstituted with 2 mL bacteriostatic water each (2,500 mcg/mL). Under those conditions:
- 250 mcg BPC-157 = 0.1 mL = 10 units on a U-100 syringe
- 2,500 mcg TB-500 = 1.0 mL = 100 units on a U-100 syringe (the full barrel)
Use the calculators on the BPC-157 and TB-500 pages to model other volumes.
Reported outcomes
Animal-model literature reports accelerated tendon and ligament healing when the two peptides are combined with post-injury administration. No human randomised trials have compared the combination against either peptide alone or placebo.